The GLP-1 Revolution: What Happens When a Billion-Dollar Appetite Shifts?

GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound are disrupting every industry. But their impact goes far beyond just weight loss.​

These medications are reshaping behaviors, consumption habits, and broader lifestyle choices.

With 1 in 8 Americans now using a GLP-1, these drugs are transforming consumer demand across key verticals—from beauty, fashion, and fitness to travel and healthcare. The behavioral shifts are real: desire for new types of food & beverages, new experiences, new hobbies, changes in physical activity, etc.—and they’re already showing up in search, retail data, and brand engagement.​

This panel will explore the range of opportunities and potential risks that come with the GLP-1 disruption. We’ll look at what real-time behavioral signals are emerging on platforms and what it means for brands navigating this rapidly shifting landscape.​

With the global GLP-1 market projected to approach $500 billion by 2030, the question isn’t if your category will be affected, but how soon.

EVENT DETAILS:​
Panel: 30 minutes​
Audience Q&A: 10-15 minutes​
Drinks/networking mixer: 45 minutes​.